Table 2.
Solid organ transplant cohort.
| Organ | Cancer | Age | Gender | Immunotherapy | Immunosuppression | Toxicity | Response |
|---|---|---|---|---|---|---|---|
| Kidney | Melanoma | 65 | M | Sequential pembrolizumab + ipilimumab | Prednisone, mycophenolate and everolimus | G2 pneumonitis | PD |
| Kidney | Melanoma | 70 | M | Pembrolizumab | Tacrolimus and prednisone | – | PD |
| Kidney | Melanoma | 75 | M | Pembrolizumab | Prednisone | – | PR |
| Kidney | Melanoma | 65 | M | Pembrolizumab | Prednisone, mycophenolate and tacrolimus | – | PD |
| Kidney | Melanoma | 48 | M | Nivolumab | Prednisone and tacrolimus | G4 acute rejection of kidney transplant resulting in graft failure, requiring dialysis | PR |
| Liver | Melanoma | 63 | F | Pembrolizumab | Cyclosporine | G5 acute rejection of liver transplant. Death within 18 days of the first cycle |
NE |
PR: partial response; PD: disease progression; irAE: immune-related adverse event; NE; not evaluable.